Adverse Reactions to β2-Agonist Bronchodilators View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1986-08

AUTHORS

K. M. Lulich, R. G. Goldie, G. Ryan, J. W. Paterson

ABSTRACT

Summaryβ2-Agonists are safe and effective bronchodilator drugs. Their major adverse effects of skeletal muscle tremor, tachycardia and various metabolic effects are mediated by β-adrenoceptor stimulation and are reversible. Skeletal muscle tremor is the most frequent dose-limiting side effect. It may be reduced by commencing treatment with a low dose and if it persists another β2-agonist may be tried. Other side effects such as cardiac arrhythmias and reduction in PaO2 are a serious potential problem in some susceptible asthmatics. However, they are infrequent or of a mild degree and are generally outweighed by the good control of asthma produced by β2-agonists.Side effects from β2-agonist therapy can be minimised by use of the inhaled route which selectively delivers the drug to the airways. Furthermore, selective tolerance develops to their side effects. The dose of a β2-agonist should be assessed on the basis of therapeutic effect and the level of tolerance to its side effects. Recommended doses of β2-agonists used for long term therapy do not cause clinically significant desensitisation of airway β-adrenoceptors, although this may become a relevant problem in patients who are regularly receiving very high doses.Intravenous β2-agonists have a place in the treatment of severe asthma not responding to nebuliser therapy. In this life-threatening situation with severe airflow obstruction, monitoring of heart rate, PaO2, plasma potassium and the electrocardiogram should be mandatory and supplemental oxygen given so that serious adverse effects are prevented. More... »

PAGES

286-299

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf03259844

DOI

http://dx.doi.org/10.1007/bf03259844

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037870887

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2878344


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchodilator Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pregnancy", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415461.3", 
          "name": [
            "Department of Pharmacology, University of Western Australia, 6009, Nedlands, WA, Australia", 
            "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lulich", 
        "givenName": "K. M.", 
        "id": "sg:person.0630076733.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630076733.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415461.3", 
          "name": [
            "Department of Pharmacology, University of Western Australia, 6009, Nedlands, WA, Australia", 
            "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldie", 
        "givenName": "R. G.", 
        "id": "sg:person.01227764644.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227764644.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415461.3", 
          "name": [
            "Department of Pharmacology, University of Western Australia, 6009, Nedlands, WA, Australia", 
            "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ryan", 
        "givenName": "G.", 
        "id": "sg:person.01171476770.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171476770.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415461.3", 
          "name": [
            "Department of Pharmacology, University of Western Australia, 6009, Nedlands, WA, Australia", 
            "Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paterson", 
        "givenName": "J. W.", 
        "id": "sg:person.012601677762.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012601677762.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/clpt.1984.108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052737272", 
          "https://doi.org/10.1038/clpt.1984.108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01219422", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051525914", 
          "https://doi.org/10.1007/bf01219422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1982.102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003364349", 
          "https://doi.org/10.1038/clpt.1982.102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00432181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042024017", 
          "https://doi.org/10.1007/bf00432181"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1986-08", 
    "datePublishedReg": "1986-08-01", 
    "description": "Summary\u03b22-Agonists are safe and effective bronchodilator drugs. Their major adverse effects of skeletal muscle tremor, tachycardia and various metabolic effects are mediated by \u03b2-adrenoceptor stimulation and are reversible. Skeletal muscle tremor is the most frequent dose-limiting side effect. It may be reduced by commencing treatment with a low dose and if it persists another \u03b22-agonist may be tried. Other side effects such as cardiac arrhythmias and reduction in PaO2 are a serious potential problem in some susceptible asthmatics. However, they are infrequent or of a mild degree and are generally outweighed by the good control of asthma produced by \u03b22-agonists.Side effects from \u03b22-agonist therapy can be minimised by use of the inhaled route which selectively delivers the drug to the airways. Furthermore, selective tolerance develops to their side effects. The dose of a \u03b22-agonist should be assessed on the basis of therapeutic effect and the level of tolerance to its side effects. Recommended doses of \u03b22-agonists used for long term therapy do not cause clinically significant desensitisation of airway \u03b2-adrenoceptors, although this may become a relevant problem in patients who are regularly receiving very high doses.Intravenous \u03b22-agonists have a place in the treatment of severe asthma not responding to nebuliser therapy. In this life-threatening situation with severe airflow obstruction, monitoring of heart rate, PaO2, plasma potassium and the electrocardiogram should be mandatory and supplemental oxygen given so that serious adverse effects are prevented.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf03259844", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096281", 
        "issn": [
          "0114-5916", 
          "1179-1942"
        ], 
        "name": "Drug Safety", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "1"
      }
    ], 
    "keywords": [
      "skeletal muscle tremor", 
      "side effects", 
      "frequent dose-limiting side effect", 
      "muscle tremors", 
      "dose-limiting side effect", 
      "effective bronchodilator drug", 
      "adverse effects", 
      "\u03b22-agonist therapy", 
      "severe airflow obstruction", 
      "long-term therapy", 
      "serious adverse effects", 
      "major adverse effects", 
      "\u03b2-adrenoceptor stimulation", 
      "life-threatening situations", 
      "nebuliser therapy", 
      "severe asthma", 
      "airflow obstruction", 
      "agonist bronchodilators", 
      "supplemental oxygen", 
      "term therapy", 
      "bronchodilator drugs", 
      "plasma potassium", 
      "\u03b2-adrenoceptors", 
      "adverse reactions", 
      "mild degree", 
      "therapeutic effect", 
      "metabolic effects", 
      "\u03b22 agonists", 
      "low dose", 
      "heart rate", 
      "cardiac arrhythmias", 
      "high doses", 
      "therapy", 
      "selective tolerance", 
      "PaO2", 
      "asthma", 
      "dose", 
      "doses", 
      "tremor", 
      "drugs", 
      "treatment", 
      "asthmatics", 
      "bronchodilators", 
      "tachycardia", 
      "airway", 
      "patients", 
      "arrhythmias", 
      "obstruction", 
      "desensitisation", 
      "electrocardiogram", 
      "serious potential problem", 
      "stimulation", 
      "effect", 
      "better control", 
      "tolerance", 
      "levels", 
      "potential problems", 
      "control", 
      "rate", 
      "potassium", 
      "reduction", 
      "monitoring", 
      "use", 
      "level of tolerance", 
      "relevant problems", 
      "degree", 
      "route", 
      "basis", 
      "reaction", 
      "situation", 
      "problem", 
      "oxygen", 
      "place"
    ], 
    "name": "Adverse Reactions to \u03b22-Agonist Bronchodilators", 
    "pagination": "286-299", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037870887"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf03259844"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2878344"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf03259844", 
      "https://app.dimensions.ai/details/publication/pub.1037870887"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_193.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf03259844"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03259844'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03259844'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03259844'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03259844'


 

This table displays all metadata directly associated to this object as RDF triples.

196 TRIPLES      21 PREDICATES      109 URIs      96 LITERALS      12 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf03259844 schema:about N014c6c90d2ee47baba32d44f31d861dc
2 N03c1d5043c7e4c18944af1d305e28203
3 N3ce8e51182dd4be886aa78f8b1e4f6e1
4 N4c403cd3731641d0bb7149789e9d3f3f
5 N8161e822dd9941538ab3091f3b037a73
6 anzsrc-for:11
7 anzsrc-for:1102
8 anzsrc-for:1115
9 schema:author N9a27adbdfec8474e8fd52e1b1ca70a2a
10 schema:citation sg:pub.10.1007/bf00432181
11 sg:pub.10.1007/bf01219422
12 sg:pub.10.1038/clpt.1982.102
13 sg:pub.10.1038/clpt.1984.108
14 schema:datePublished 1986-08
15 schema:datePublishedReg 1986-08-01
16 schema:description Summaryβ2-Agonists are safe and effective bronchodilator drugs. Their major adverse effects of skeletal muscle tremor, tachycardia and various metabolic effects are mediated by β-adrenoceptor stimulation and are reversible. Skeletal muscle tremor is the most frequent dose-limiting side effect. It may be reduced by commencing treatment with a low dose and if it persists another β2-agonist may be tried. Other side effects such as cardiac arrhythmias and reduction in PaO2 are a serious potential problem in some susceptible asthmatics. However, they are infrequent or of a mild degree and are generally outweighed by the good control of asthma produced by β2-agonists.Side effects from β2-agonist therapy can be minimised by use of the inhaled route which selectively delivers the drug to the airways. Furthermore, selective tolerance develops to their side effects. The dose of a β2-agonist should be assessed on the basis of therapeutic effect and the level of tolerance to its side effects. Recommended doses of β2-agonists used for long term therapy do not cause clinically significant desensitisation of airway β-adrenoceptors, although this may become a relevant problem in patients who are regularly receiving very high doses.Intravenous β2-agonists have a place in the treatment of severe asthma not responding to nebuliser therapy. In this life-threatening situation with severe airflow obstruction, monitoring of heart rate, PaO2, plasma potassium and the electrocardiogram should be mandatory and supplemental oxygen given so that serious adverse effects are prevented.
17 schema:genre article
18 schema:isAccessibleForFree false
19 schema:isPartOf N441ead8b6a6c436da10ad57fefbf18c3
20 Na05f32781026440296c32ec524d94cba
21 sg:journal.1096281
22 schema:keywords PaO2
23 adverse effects
24 adverse reactions
25 agonist bronchodilators
26 airflow obstruction
27 airway
28 arrhythmias
29 asthma
30 asthmatics
31 basis
32 better control
33 bronchodilator drugs
34 bronchodilators
35 cardiac arrhythmias
36 control
37 degree
38 desensitisation
39 dose
40 dose-limiting side effect
41 doses
42 drugs
43 effect
44 effective bronchodilator drug
45 electrocardiogram
46 frequent dose-limiting side effect
47 heart rate
48 high doses
49 level of tolerance
50 levels
51 life-threatening situations
52 long-term therapy
53 low dose
54 major adverse effects
55 metabolic effects
56 mild degree
57 monitoring
58 muscle tremors
59 nebuliser therapy
60 obstruction
61 oxygen
62 patients
63 place
64 plasma potassium
65 potassium
66 potential problems
67 problem
68 rate
69 reaction
70 reduction
71 relevant problems
72 route
73 selective tolerance
74 serious adverse effects
75 serious potential problem
76 severe airflow obstruction
77 severe asthma
78 side effects
79 situation
80 skeletal muscle tremor
81 stimulation
82 supplemental oxygen
83 tachycardia
84 term therapy
85 therapeutic effect
86 therapy
87 tolerance
88 treatment
89 tremor
90 use
91 β-adrenoceptor stimulation
92 β-adrenoceptors
93 β2 agonists
94 β2-agonist therapy
95 schema:name Adverse Reactions to β2-Agonist Bronchodilators
96 schema:pagination 286-299
97 schema:productId N5b3fa48b5a064691b5bde0d2f37ddf5e
98 Ncf198043271f4c97ae3f248ed0e78d7c
99 Nfecb6c1c5acf469f811b369b27e876af
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037870887
101 https://doi.org/10.1007/bf03259844
102 schema:sdDatePublished 2022-09-02T15:46
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N1c1b5738fb5b4f75bc5f8e17cc9d1aee
105 schema:url https://doi.org/10.1007/bf03259844
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N014c6c90d2ee47baba32d44f31d861dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Pregnancy
111 rdf:type schema:DefinedTerm
112 N03c1d5043c7e4c18944af1d305e28203 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Female
114 rdf:type schema:DefinedTerm
115 N1c1b5738fb5b4f75bc5f8e17cc9d1aee schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N3ce8e51182dd4be886aa78f8b1e4f6e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Humans
119 rdf:type schema:DefinedTerm
120 N41ad1a4e2dad463ea60b9fc454ef3c77 rdf:first sg:person.012601677762.00
121 rdf:rest rdf:nil
122 N441ead8b6a6c436da10ad57fefbf18c3 schema:issueNumber 4
123 rdf:type schema:PublicationIssue
124 N4c403cd3731641d0bb7149789e9d3f3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Bronchodilator Agents
126 rdf:type schema:DefinedTerm
127 N5b3fa48b5a064691b5bde0d2f37ddf5e schema:name dimensions_id
128 schema:value pub.1037870887
129 rdf:type schema:PropertyValue
130 N8161e822dd9941538ab3091f3b037a73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Adrenergic beta-Agonists
132 rdf:type schema:DefinedTerm
133 N940bca805acd4c2dbf636b0605e1e34b rdf:first sg:person.01171476770.60
134 rdf:rest N41ad1a4e2dad463ea60b9fc454ef3c77
135 N9a27adbdfec8474e8fd52e1b1ca70a2a rdf:first sg:person.0630076733.21
136 rdf:rest Na4758a6d7e3d4c13a5606cc23478d297
137 Na05f32781026440296c32ec524d94cba schema:volumeNumber 1
138 rdf:type schema:PublicationVolume
139 Na4758a6d7e3d4c13a5606cc23478d297 rdf:first sg:person.01227764644.43
140 rdf:rest N940bca805acd4c2dbf636b0605e1e34b
141 Ncf198043271f4c97ae3f248ed0e78d7c schema:name pubmed_id
142 schema:value 2878344
143 rdf:type schema:PropertyValue
144 Nfecb6c1c5acf469f811b369b27e876af schema:name doi
145 schema:value 10.1007/bf03259844
146 rdf:type schema:PropertyValue
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
151 schema:name Cardiorespiratory Medicine and Haematology
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
154 schema:name Pharmacology and Pharmaceutical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1096281 schema:issn 0114-5916
157 1179-1942
158 schema:name Drug Safety
159 schema:publisher Springer Nature
160 rdf:type schema:Periodical
161 sg:person.01171476770.60 schema:affiliation grid-institutes:grid.415461.3
162 schema:familyName Ryan
163 schema:givenName G.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171476770.60
165 rdf:type schema:Person
166 sg:person.01227764644.43 schema:affiliation grid-institutes:grid.415461.3
167 schema:familyName Goldie
168 schema:givenName R. G.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227764644.43
170 rdf:type schema:Person
171 sg:person.012601677762.00 schema:affiliation grid-institutes:grid.415461.3
172 schema:familyName Paterson
173 schema:givenName J. W.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012601677762.00
175 rdf:type schema:Person
176 sg:person.0630076733.21 schema:affiliation grid-institutes:grid.415461.3
177 schema:familyName Lulich
178 schema:givenName K. M.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630076733.21
180 rdf:type schema:Person
181 sg:pub.10.1007/bf00432181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042024017
182 https://doi.org/10.1007/bf00432181
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/bf01219422 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051525914
185 https://doi.org/10.1007/bf01219422
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/clpt.1982.102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003364349
188 https://doi.org/10.1038/clpt.1982.102
189 rdf:type schema:CreativeWork
190 sg:pub.10.1038/clpt.1984.108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052737272
191 https://doi.org/10.1038/clpt.1984.108
192 rdf:type schema:CreativeWork
193 grid-institutes:grid.415461.3 schema:alternateName Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia
194 schema:name Department of Pharmacology, University of Western Australia, 6009, Nedlands, WA, Australia
195 Department of Respiratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth, Australia
196 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...